I was thinking 2 years time...............lol.
Printable View
I maintain they need a buy one get one free on the blackcurrant thingies at $34.99 and the shares at 59 cents.
They are only now available online from www.aioranz.com
I signed up to their newsletter thingy. Next time they have a decent special I'll help you guys out.
My nose for finding a feed or smelling trouble coming still works really well but if I don't get some more of those blackcurrant thingies for my eyes I might need to adopt my own seeing eye dog lol
Think they will help you out more than us.After all it is your eyes we are talking about.
Order now and be done with it.Don't muck about with your eyes.
I find my bone and joint AiOra work really well, and at full price just $1 a day they are well worth the money..
Then next time they are on special load up on them.I certainly will be.
Fair point mate. As much as I hate paying full retail I think they are making a difference. Retiring early would probably be better for my eyes but that costs more that $1 a day lol
My optometrist recommended a daily brazil nut for the eyes a few years ago - a few tasty cents a day for selenium - and my vision has actually improved :) Not sure if it's that or putting frozen blueberries on my morning cereal - also highly recommended for health and taste. But good on you all for supporting PAZ!
You're preaching to the converted mate. I have a lot of lifestyle idea's we're working on as I continue the slide from semi retired to mostly retired and then fully retired. I've seen a few reports now that all say essentially the same thing. A hard retirement date is not a good idea. A gradual slide into first, semi retirement, (where I've been for years), and then gradually more and more retired is way better for you in every way.
Annual Result is out:
PharmaZen_FY2021_April_release_Final.pdf (usx.co.nz)
UNAUDITED RESULTS FOR THE YEAR TO 31 DECEMBER 2021
PharmaZen reports second half FY21 recovery as it navigates supply and COVID disruptionsChristchurch biotechnology company PharmaZen (USX.PAZ) today reports FY2021 results showing, as signalled at the half year release, a stronger financial performance in the second half than the first half. T
he improvement follows continuing strong demand for its nutraceutical products and successful adaptation to the constraints of the COVID-19 pandemic with the associated ongoing global supply chain challenges.Revenue1for the year to 31 December 2021 was only marginally weaker at $20.5m from $21.5m in the prior year, an outstanding outcome given the often severe covid imposed operating constraints throughout the year.
Most pleasingly there was an 18% sequential improvement in second half revenue to $11.1m, offsetting the weaker $9.4m result in the first half when disruptions to production were at their peak.Underlying EBITDA2for the year dropped from $6.7m in 2020 to $2.3m, however the second half year represented a significant turnaround with underlying EBITDA more than $1.5m up from the $776k achieved in the six months to the end of June 2021.
The company is meanwhile underpinned by a strong balance sheet and solid operating cashflow. Chair Ken Fergus said: “As we detailed at the half year result, COVID-19 related travel and freight restrictions, along with a four-month shut down of the company’s largest freeze dryer to install a new one without overseas engineering support, saw the company running at a loss for the first four months of the year.
“In the second half of the year these challenges continued. We have faced difficulties freighting finished goods to our offshore customers and importing equipment to meet the demand. We have also faced high staff vacancy rates (over 20%) and intense competition for skilled labour alongside the ongoing difficulties of importing engineers because of COVID-19 border restrictions.
“However, PharmaZen has mitigated what must be seen as a ‘perfect storm’ with the entire team stepping up to meet these pressures and deliver for our customers,” Mr Fergus said. “The easy option was to postpone developments until the borders reopened, however we backed ourselves to undertake the installation and commissioning work that would have previously fallen to equipment suppliers.
This meant building an entire engineering team from ground up to work with some very novel technologies.”Key achievements over the half year have included:
• The completion of the Nuttall Drive facility, including the installation of a 2,000kg dryer.
• The installation of a new 2,000kg dryer at the Port Hills Road facility.The installation of a new Energy Hub at the Port Hills Road facility.
• Completion of the Tawhiri building to a stage where we can commence installation and internal fitoutThe majority of the new equipment for our site at Tawhiri is now in New Zealand with the exception of the next two energy hubs (shipping in April) and three new freeze dryers also scheduled to start shipping in April.
“These challenges have in some measure made the company stronger” Mr Fergus said. “Notably, the experience the team has gained on the initial installations means we now have a selfsufficient engineering team. This capability promises to not only serve us well amid the continuing disruptions, but well into the future.
”Outlook Mr Fergus said the company is pleased with the progress it has made in the first quarter of the new financial year, albeit recognising the continuing challenges posed by the supply chain and those that are emerging with COVID-19 endemic in the community. Given that demand for the company’s products continues to outstrip capacity the company is now reviewing options for bringing forward the commencement of the build at the second facility at Tawhiri.
“The growth opportunities in core products remain strong but we are constantly looking for additional opportunities to grow the company with our new investor providing valuable input.“PharmaZen is well positioned to continue the recovery it has seen in the second half of the financial year. We are targeting the dryers at the Port Hills Road and Nuttall Drive facilities to be running by the end of the third quarter, representing a doubling in our freeze-drying capacity” Mr Fergus said.
“The company also has a number of other already well researched and considered new product development opportunities that the Board is very excited by. These opportunities, coupled with continuing strong demand for our existing products, an easing of border restrictions and our newly developed engineering capabilities, position PharmaZen for a substantially better result for the new financial year.”
A very good update.